دورية أكاديمية
Real-world study on microsatellite instability and mismatch repair deficiency testing patterns among patients with metastatic colorectal cancer in Spain.
| العنوان: | Real-world study on microsatellite instability and mismatch repair deficiency testing patterns among patients with metastatic colorectal cancer in Spain. |
|---|---|
| المؤلفون: | Garcia-Carbonero R; Medical Oncology Department, Hospital Universitario 12 de Octubre, IIS Imas12, UCM, Av Cordoba S/N, 28041, Madrid, Spain. rgcarbonero@gmail.com., González Astorga B; Medical Oncology Department, Hospital Universitario Clínico San Cecilio, Granada, Spain., Vidal Tocino R; Medical Oncology Department, Complejo Asistencial Universitario de Salamanca, IBSAL, Salamanca, Spain., Contreras Toledo D; Medical Oncology Department, Hospital Universitario Central de Asturias, ISPA, Programa Doctorado en Ciencias de la Salud, Universidad de Oviedo, Oviedo, Spain., Pericay C; Medical Oncology Department, Hospital Universitari Parc Taulí, Sabadell, Spain., Fernández Montes A; Medical Oncology Department, Complexo Hospitalario Universitario de Ourense, Ourense, Spain., Falcó E; Medical Oncology Department, Hospital Son Llatzer, Palma, Spain., González Cordero M; Medical Oncology Department, Hospital Universitario de Badajoz, Badajoz, Spain., Reina Zoilo JJ; Medical Oncology Department, Hospital Universitario Virgen Macarena, Sevilla, Spain., Alonso V; Medical Oncology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain., Rodríguez Salas N; Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain., Gil-Raga M; Medical Oncology Department, Hospital General Universitario de Valencia, Valencia, Spain., Santos C; Medical Oncology Department, Institute Català d'Oncologia IDIBELL, L'Hospitalet, Barcelona, Spain., Páez D; Medical Oncology Department, U705 (CIBERER), Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., Anton-Pascual B; Medical Oncology Department, Hospital Universitario 12 de Octubre, IIS Imas12, UCM, Av Cordoba S/N, 28041, Madrid, Spain., Aguilar F; Medical Affairs Department, MSD Spain, C/Josefa Valcarcel, 38, 28027, Madrid, Spain. fernando.aguilar@merck.com., Morales P; Medical Affairs Department, MSD Spain, C/Josefa Valcarcel, 38, 28027, Madrid, Spain. |
| المصدر: | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2024 Apr; Vol. 26 (4), pp. 864-871. Date of Electronic Publication: 2023 Aug 31. |
| نوع المنشور: | Journal Article; Multicenter Study; Observational Study |
| اللغة: | English |
| بيانات الدورية: | Publisher: Country of Publication: Italy NLM ID: 101247119 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1699-3055 (Electronic) Linking ISSN: 1699048X NLM ISO Abbreviation: Clin Transl Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2010- >: Milan : Springer Italia Original Publication: Barcelona, Spain : Doyma, c2005- |
| مواضيع طبية MeSH: | Brain Neoplasms* , Colonic Neoplasms*/pathology , Colorectal Neoplasms*/diagnosis , Colorectal Neoplasms*/genetics , Colorectal Neoplasms*/drug therapy , Neoplastic Syndromes, Hereditary* , Rectal Neoplasms*, Aged ; Humans ; Microsatellite Instability ; Retrospective Studies ; Spain |
| مستخلص: | Purpose: Clinical practice guidelines recommend that all patients with metastatic colorectal cancer (mCRC) should be tested for mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H). We aimed to describe the dMMR/MSI-H testing practice in patients with mCRC in Spanish centers. Methods: Multicenter, observational retrospective study that included patients newly diagnosed with mCRC or who progressed to a metastatic stage from early/localized stages. Results: Three hundred patients were included in the study from May 2020 through May 2021, with a median age of 68 years, and two hundred twenty-five (75%) had stage IV disease at initial diagnosis; two hundred eighty-four patients received first-line treatment, and dMMR/MSI-H testing was performed in two hundred fifty-one (84%) patients. The results of the dMMR/MSI-H tests were available in 61 (24%) of 251 patients before the diagnosis of metastatic disease and in 191 (81%) of 236 evaluable patients for this outcome before the initiation of first-line treatment. Among the 244 patients who were tested for dMMR/MSI-H with IHC or PCR, 14 (6%) were MMR deficient. The most frequent type of first-line treatment was the combination of chemotherapy and biological agent, that was received by 71% and 50% of patients with MMR proficient and deficient tumors, respectively, followed by chemotherapy alone, received in over 20% of patients in each subgroup. Only 29% of dMMR/MSI-H tumors received first-line immunotherapy. Conclusion: Our study suggests that a high proportion of patients with mCRC are currently tested for dMMR/MSI-H in tertiary hospitals across Spain. However, there is still room for improvement until universal testing is achieved. Trial Registration: Not applicable. (© 2023. The Author(s).) |
| References: | Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. https://doi.org/10.3322/caac.21660 . (PMID: 10.3322/caac.2166033538338) Ouakrim DA, Pizot C, Boniol M, Malvezzi M, Boniol M, Negri E, et al. Trends in colorectal cancer mortality in Europe: retrospective analysis of the WHO mortality database. BMJ. 2015;351:h4970. https://doi.org/10.1136/bmj.h4970 . (PMID: 10.1136/bmj.h4970) American Cancer Society. Colorectal cancer facts & figures 2020–2022. 2022. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/colorectal-cancer-facts-and-figures/colorectal-cancer-facts-and-figures-2020-2022.pdf . Chiorean EG, Nandakumar G, Fadelu T, Temin S, Alarcon-Rozas AE, Bejarano S, et al. Treatment of patients with late-stage colorectal cancer: ASCO resource-stratified guideline. JCO Glob Oncol. 2020;6:414–38. https://doi.org/10.1200/JGO.19.00367 . (PMID: 10.1200/JGO.19.0036732150483) Yoshino T, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu RH, et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS SSO and TOS. Ann Oncol. 2018;29:44–70. https://doi.org/10.1093/annonc/mdx738 . (PMID: 10.1093/annonc/mdx73829155929) National Comprehensive Cancer Network. Colon cancer. Version 1.2022. 2022. https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf . Accessed 25 Feb 2022. Zhao P, Li L, Jiang X, Li Q. Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy. J Hematol Oncol. 2019;12:54. https://doi.org/10.1186/s13045-019-0738-1 . (PMID: 10.1186/s13045-019-0738-1311514826544911) Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–20. https://doi.org/10.1056/NEJMoa1500596 . (PMID: 10.1056/NEJMoa1500596260282554481136) Le DT, Kim TW, Van Cutsem E, Geva R, Jager D, Hara H, et al. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J Clin Oncol. 2020;38:11–9. https://doi.org/10.1200/JCO.19.02107 . (PMID: 10.1200/JCO.19.0210731725351) Andre T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383:2207–18. https://doi.org/10.1056/NEJMoa2017699 . (PMID: 10.1056/NEJMoa201769933264544) Diaz LA Jr, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 2022;23:659–70. https://doi.org/10.1016/S1470-2045(22)00197-8 . (PMID: 10.1016/S1470-2045(22)00197-8354274719533375) Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18:1182–91. https://doi.org/10.1016/S1470-2045(17)30422-9 . (PMID: 10.1016/S1470-2045(17)30422-9287347596207072) Lenz HJ, Van Cutsem E, Luisa Limon M, Wong KYM, Hendlisz A, Aglietta M, et al. First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study. J Clin Oncol. 2022;40:161–70. https://doi.org/10.1200/jco.21.01015 . (PMID: 10.1200/jco.21.0101534637336) Food and Drug Administration. JEMPERLI. Full prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761174s003s004lbl.pdf . Accessed July 31st, 2023. 2023. European Medicines Agency. KEYTRUDA. Summary of product characteristics. 2022. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf . Cervantes A, Adam R, Rosello S, Arnold D, Normanno N, Taieb J, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:10–32. https://doi.org/10.1016/j.annonc.2022.10.003 . (PMID: 10.1016/j.annonc.2022.10.00336307056) Mascarenhas L, Shanley S, Mitchell G, Spurdle AB, Macrae F, Pachter N, et al. Current mismatch repair deficiency tumor testing practices and capabilities: a survey of Australian pathology providers. Asia Pac J Clin Oncol. 2018;14:417–25. https://doi.org/10.1111/ajco.13076 . (PMID: 10.1111/ajco.1307630294856) Gutierrez ME, Price KS, Lanman RB, Nagy RJ, Shah I, Mathura S, et al. Genomic profiling for KRAS, NRAS, BRAF, microsatellite instability, and mismatch repair deficiency among patients with metastatic colon cancer. JCO Precis Oncol. 2019;3:1–9. https://doi.org/10.1200/PO.19.00274 . (PMID: 10.1200/PO.19.00274) Shaikh T, Handorf EA, Meyer JE, Hall MJ, Esnaola NF. Mismatch repair deficiency testing in patients with colorectal cancer and nonadherence to testing guidelines in young adults. JAMA Oncol. 2018;4:e173580. https://doi.org/10.1001/jamaoncol.2017.3580 . (PMID: 10.1001/jamaoncol.2017.358029121143) Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th ed. New York: Springer; 2010. Aranda E, Polo E, Camps C, Carrato A, Diaz-Rubio E, Guillem V, et al. Treatment patterns for metastatic colorectal cancer in Spain. Clin Transl Oncol. 2020;22:1455–62. https://doi.org/10.1007/s12094-019-02279-5 . (PMID: 10.1007/s12094-019-02279-5319748197381444) Assasi N, Blackhouse G, Campbell K, Gaebel K, Hopkins R, Jegathisawaran J, et al. CADTH optimal use reports. DNA mismatch repair deficiency tumour testing for patients with colorectal cancer: a health technology assessment. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health; 2016. Kang YJ, Killen J, Caruana M, Simms K, Taylor N, Frayling IM, et al. The predicted impact and cost-effectiveness of systematic testing of people with incident colorectal cancer for Lynch syndrome. Med J Aust. 2020;212:72–81. https://doi.org/10.5694/mja2.50356 . (PMID: 10.5694/mja2.5035631595523) Luchini C, Bibeau F, Ligtenberg MJL, Singh N, Nottegar A, Bosse T, et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol. 2019;30:1232–43. https://doi.org/10.1093/annonc/mdz116 . (PMID: 10.1093/annonc/mdz11631056702) Battaglin F, Naseem M, Lenz HJ, Salem ME. Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives. Clin Adv Hematol Oncol. 2018;16:735–45. (PMID: 305435897493692) Lorenzi M, Amonkar M, Zhang J, Mehta S, Liaw K-L. Epidemiology of microsatellite instability high (MSI-H) and deficient mismatch repair (dMMR) in solid tumors: a structured literature review. J Oncol. 2020;2020:1–17. https://doi.org/10.1155/2020/1807929 . (PMID: 10.1155/2020/1807929) Waller J, Gu L, De Hoedt AM, Freedland SJ, Wang T, Amonkar M, et al. DNA mismatch repair and microsatellite instability in colorectal tumors: an observational study in the Veterans Affairs Health Care System. Future Oncol. 2022;18:649–60. https://doi.org/10.2217/fon-2021-0874 . (PMID: 10.2217/fon-2021-087435068195) Yang RK, Chen H, Roy-Chowdhuri S, Rashid A, Alvarez H, Routbort M, et al. Clinical testing for mismatch repair in neoplasms using multiple laboratory methods. Cancers (Basel). 2022;14:4550. https://doi.org/10.3390/cancers14194550 . (PMID: 10.3390/cancers1419455036230473) |
| فهرسة مساهمة: | Keywords: Metastatic colorectal cancer; Microsatellite instability; Microsatellite stable; Mismatch repair deficiency; Real-world evidence |
| SCR Disease Name: | Turcot syndrome |
| تواريخ الأحداث: | Date Created: 20230831 Date Completed: 20240401 Latest Revision: 20240708 |
| رمز التحديث: | 20240708 |
| مُعرف محوري في PubMed: | PMC10981578 |
| DOI: | 10.1007/s12094-023-03309-z |
| PMID: | 37651021 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1699-3055 |
|---|---|
| DOI: | 10.1007/s12094-023-03309-z |